Replimune Q1 net loss $49.6M; CERPASS data delayed to early Q4; inks Incyte CSCC trial

Replimune Group, Inc.

2024-Q1 EPS reported -$0.75

Net loss $49.6M in fiscal Q1 vs $42.3M a year ago; cash $539.1M provides runway into H2 2025.
CERPASS topline data (RP1+Libtayo in CSCC) expected early Q4 2023, delayed from Q3 due to slower independent review.
IGNYTE full cohort snapshot (N=141) in anti-PD1 failed melanoma on track for Q4 2023; BLA submission planned Q1/Q2 2024.
Clinical trial collaboration with Incyte to test RP1 + oral PD-L1 INCB99280 in neoadjuvant CSCC; trial to start early 2024, costs shared.
RP2/RP3 Phase 2 programs: third-line CRC trial initiated; HCC trial expected this quarter; Phase 1 completion in Q3 2023.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Replimune Group, Inc. reported financial results for fiscal first quarter ended June 30, 2023.

Period: fiscal first quarter ended June 30, 2023
Result: reported results

Exact text from the filing

On August 3, 2023, Replimune Group, Inc. (the “Company”) issued a news release announcing its financial results for the first quarter ended June 30, 2023

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Replimune Group, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-087059

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.